Banned medicine (Credit-Canva)
The Union Health Ministry implemented a ban on 156 "irrational" FDC medicines, effective immediately. These medicines, including widely used antibiotics, painkillers, and multivitamins, were commonly used to treat fever, cough, and infections. The ban was imposed due to the associated health risks and lack of therapeutic justification for the ingredients in these FDCs.
FDCs or fixed-dosed combinations, also known as "cocktail drugs," are medications that combine multiple drugs in a single pill. They are designed to treat multiple symptoms or conditions simultaneously. While they offer convenience, they can pose significant risks. These risks include the possibility of overdose, adverse interactions between the drugs, and the development of antibiotic resistance. Additionally, many FDC medicines lack sufficient scientific evidence to support their safety and efficacy.
Experts have raised concerns about the use of FDC medicines. They believe that many of these combinations lack sufficient scientific evidence to support their safety and effectiveness. Additionally, the combination of multiple drugs in a single pill can increase the risk of adverse side effects and interactions with other medications.
Experts have also found that FDC medicines may not be as effective as individual drugs in treating certain conditions. It is important to note that safer and more effective alternatives are available for most of the medical conditions that FDC medicines were used to treat. One particular concern is the inclusion of antibiotics in some FDCs. Overuse of antibiotics can contribute to the development of antibiotic resistance, a major public health threat.
The use of FDC medicines can lead to adverse effects, including serious ones. Additionally, safer alternatives, tested in clinical trials, are available to treat the same medical conditions. Experts recommend prescribing drugs individually based on a patient's clinical symptoms rather than combining them in FDCs.
The ban on irrational FDC medicines by the Union Health Ministry can be seen as a positive step towards promoting rational drug use and protecting public health. The goal is to eliminate unnecessary and potentially harmful drug combinations. This is a step forward in reducing the risks associated with medication and ensure safer and more effective treatment options for patients.
Credit: iStock
The World Health Organization today declared the Ebola outbreak in the Democratic Republic of the Congo and Uganda a “public health emergency of international concern” (PHEIC), citing the risk of spread to neighboring countries.
The WHO defines a Public Health Emergency as an extraordinary event or crisis that poses a substantial risk of widespread illness, injury, or death to a population, such as pandemics, severe pollution events, or natural disasters.
However, the WHO clarified that the outbreak, caused by the Bundibugyo virus, does not meet the criteria for a pandemic emergency. Countries sharing land borders with the DRC were described as being at high risk for further spread.
“The Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda constitutes a public health emergency of international concern (PHEIC), but does not meet the criteria of pandemic emergency, as defined in the International Health Regulations (2005) (IHR),” the WHO said in a statement.
Ebola Outbreak: Cases And Deaths
The UN health agency said the outbreak has caused 80 deaths, with eight laboratory-confirmed cases and 246 suspected Ebola cases reported in Ituri Province in the DR Congo, across Bunia, Rwampara, and Mongbwalu.
In addition, two laboratory-confirmed cases — including one death — with no apparent link to each other were reported in Kampala, Uganda, within 24 hours of each other, indicating international spread. Both individuals had travelled separately from the DR Congo.
A laboratory-confirmed case has also been reported in Kinshasa, DR Congo, involving a person returning from Ituri.
The WHO further noted unusual clusters of community deaths and said the outbreak poses a public health risk to other countries through international spread, which has already been documented.
What Is Bundibugyo Virus Disease?
Bundibugyo virus disease is a rare and deadly illness that has caused outbreaks in several African countries in the past. It is different from other known ebolaviruses such as the Zaire ebolavirus and Sudan ebolavirus.
The virus was first identified during an outbreak in 2007, which resulted in more than 100 cases before being declared over in early 2008.
The WHO described the current outbreak as “extraordinary” because there are no approved Bundibugyo virus-specific therapeutics or vaccines, unlike the Ebola-Zaire strain. Most of the country’s previous outbreaks were caused by the Zaire strain.
According to US Centers for Disease Control and Prevention (CDC), the Bundibugyo strain spreads through contact with the blood or body fluids of infected individuals or people who have died from the disease.
Transmission can also occur through contact with contaminated objects such as clothing, bedding, needles, and medical equipment, or through infected animals including bats and nonhuman primates.
Symptoms include fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising in the later stages of illness.
Read More: Can Hantavirus Spread Through Semen And Breast Milk? What Experts Say
The WHO advised immediate isolation of confirmed cases and daily monitoring of contacts. It also recommended restricting national travel for exposed individuals and avoiding international travel until 21 days after exposure.
At the same time, the agency urged countries not to close borders or restrict travel and trade out of fear, warning that such measures could lead to unmonitored informal border crossings.
Credit: iStock
Health officials at the Africa Centres for Disease Control and Prevention (Africa CDC) today confirmed that the current Ebola outbreak in the Democratic Republic of the Congo and Uganda is being caused by the rare Bundibugyo strain.
Bundibugyo ebolavirus was first isolated during an outbreak of hemorrhagic fever in Uganda in 2007. There are no vaccines or specific treatments approved to prevent or treat the Bundibugyo strain.
Preliminary laboratory results from the Institut National de Recherche Biomedicale (INRB) detected Ebola virus in 13 of 20 samples tested with the Bundibugyo Virus.
"Africa CDC is actively collaborating with health authorities in DRC, Uganda, and regional partners to deliver a coordinated response to confirmed Ebola Virus Disease cases linked to the Bundibugyo strain," the Africa CDC said in a statement.
"Rapid laboratory testing, contact tracing, cross-border surveillance, and enhanced infection prevention measures are already deployed to protect communities and stop the spread," it added.
As of the latest update from DRC, approximately 246 suspected cases and 65 deaths have been reported, mainly in Mongwalu and Rwampara health zones.
Four deaths have been reported among laboratory-confirmed cases.
Suspected cases have also been reported in Bunia and are pending confirmation. These figures remain provisional and are being validated through laboratory confirmation, line-list harmonization, contact identification, and epidemiological investigation.
Also read: Ebola Resurfaces In Eastern DR Congo In 17th Outbreak, Claims 65 Lives: All You Need To Know
Uganda’s Ministry of Health, in a statement, reported a confirmed Ebola Bundibugyo Virus Disease case in a 59-year-old Congolese male who was admitted to Kibuli Muslim Hospital on May 11 and died on May 14.
The country's officials reported the case as imported from DRC and have indicated that no local case has yet been confirmed.
Africa CDC noted that it remains concerned by the urban context of Bunia and Rwampara, with intense population movement, insecurity, mining-related mobility in Mongwalu, gaps in contact listing, infection prevention and control challenges, and the proximity of affected areas to Uganda and South Sudan.
Bundibugyo virus disease is a rare and deadly illness that has caused outbreaks in several African countries in the past.
It is also spread by contact with contaminated objects (such as clothing, bedding, needles, and medical equipment), or by contact with animals, such as bats and nonhuman primates, that are infected with BVD.
Symptoms include fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising (a late stage of illness).
Read More: National Dengue Day 2026: India Reports 6,927 Cases And 10 Deaths In 2026
The US CDC advised people to avoid:
In case of infection, the CDC advises:
Credit: AI generated image
Even as the world is still grappling with the news of a hantavirus and two separate norovirus outbreaks, the Africa Centres for Disease Control and Prevention (Africa CDC) today confirmed that the Ebola virus has resurfaced in eastern Democratic Republic of the Congo for the 17th time.
In a statement, the Africa CDC reported that there are 246 suspected cases and 65 deaths, mainly in the mining areas of Mongwalu and Rwampara, about 100 kilometers north of the provincial capital, Bunia.
While tests are being carried out to identify the strain of the virus, early indications suggest the strain is not the Zaire variant, which has been responsible for several previous outbreaks in the country, the health officials said.
The Ebola Zaire strain was prominent in Congo’s past outbreaks, including the 2018 to 2020 outbreak in the eastern region that killed more than 1,000 people.
Ebola was first discovered in 1976 in the DR Congo. This is the 17th outbreak of the deadly viral disease in the country.
As per preliminary tests conducted at the Institut National de Recherche Biomédicale (INRB) in the country's capital, Kinshasa, the Ebola virus has been detected in 13 of 20 samples analysed, following consultations with DR Congo's Ministry of Health and National Public Institute.
Of the 65 deaths, four were reported among lab-confirmed cases, Africa CDC said.
Additional suspected cases have also been reported in Ituri's provincial capital, Bunia, a densely populated urban centre near the borders with Uganda and South Sudan, raising fears of regional transmission.
All affected communities and at-risk areas have been advised to follow guidelines from the national health authorities.
Also read: More Americans Exposed To Hantavirus; 41 Under Monitoring, Says CDC
As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal.
People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person, such as saliva, urine, feces, or semen, or things that have body fluids of an infected person, like clothes or sheets.
Read More: Another Norovirus Outbreak Confirmed Aboard Cruise Ship In France; Over 1,700 People Trapped
Ebola enters the body through cuts in the skin or when one touches their eyes, nose, or mouth. Early symptoms include fever, fatigue, and headache.
It is a highly infectious and transmissible disease; in fact, there have been cases of healthcare workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.
Cases of people conducting burial ceremonies, involving direct contact with the body of the deceased, can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk or in pregnancy-related fluids and tissues.
Symptoms include:
According to the WHO, there are two vaccines against the Ebola virus. But both the Merck-developed Ervebo vaccine, administered in one dose, and Johnson & Johnson-developed Zabdeno and Mvabea vaccine, administered in a two-dose regimen, target Zaire ebolavirus.
The Ervebo vaccine is recommended for use in outbreak settings and is currently the only vaccine available in the global stockpile.
© 2024 Bennett, Coleman & Company Limited